Tumor-specific gene delivery using recombinant vaccinia virus in a rabbit model of liver metastases.
BACKGROUND
Several approaches to gene therapy for cancer have yielded promising results in rodent models. The translation of these results to the clinical realm has been delayed by the lack of tumor models in large animals. We investigated the pattern of transgene (i. e., foreign or introduced gene) expression and virus vector elimination after systemic gene delivery using a thymidine kinase-negative vaccinia virus in a rabbit model of disseminated liver metastases.


METHODS
VX-2 rabbit carcinoma cells were maintained by serial transplantation in the thigh muscles of New Zealand White rabbits, and disseminated liver metastases were established by direct injection of tumor cells into the portal vein of the animals. Different doses of a recombinant thymidine kinase-negative vaccinia virus vector encoding the firefly luciferase reporter gene (i.e., transgene) were injected into tumor-bearing rabbits. Transgene activity in tumors and other organs was measured at multiple time points thereafter. The pattern of development of antibodies against the vaccinia virus vector was also examined. Two-tailed Student's paired t test was used for comparisons of transgene activity.


RESULTS
Transgene expression was increased in tumors by at least 16-fold in comparison with expression in other tissues by day 4 after vector injection (all P<. 001) and was maintained for approximately 1 week, providing evidence of tumor-specific gene delivery in this model. Rapid elimination of the circulating vector by the host immune system was observed. Anti-vector antibodies were detectable in serum as early as day 6 and were maintained for more than 3 months.


CONCLUSIONS
Tumor-specific gene delivery is possible after systemic injection of a thymidine kinase-negative vaccinia virus vector in a model of rabbit liver metastases. Although the period of transgene expression appears limited because of a rapid immune response, the therapeutic window might be sufficient for an enzyme/prodrug gene therapy approach in clinical application.
Gnant
M F
MF
Surgery Branch, Division of Clinical Sciences, National Cancer Institute, Bethesda, MD, USA.
Noll
L A
LA
Irvine
K R
KR
Puhlmann
M
M
Terrill
R E
RE
Alexander
H R
HR
Bartlett
D L
DL
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002460:Cell Line; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D015870:Gene Expression; D017344:Genes, Insect / Q000235:genetics; D017930:Genes, Reporter / Q000235:genetics; D005814:Genes, Viral / Q000235:genetics; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000627:therapeutic use; D000882:Haplorhini; D006367:HeLa Cells; D006801:Humans; D008114:Liver Neoplasms, Experimental / Q000235:genetics* / Q000556:secondary / Q000628:therapy*; D008156:Luciferases / Q000235:genetics; D010957:Plasmids; D011817:Rabbits; D011994:Recombinant Proteins / Q000235:genetics; D013937:Thymidine Kinase / Q000172:deficiency / Q000235:genetics; D013997:Time Factors; D019076:Transgenes / Q000235:genetics*; D014616:Vaccinia virus / Q000201:enzymology / Q000235:genetics* / Q000276:immunology
D000914:Antibodies, Viral; D011994:Recombinant Proteins; D008156:Luciferases; D013937:Thymidine Kinase